111 Capital’s Repligen RGEN Stock Holding History

111 Capital’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,882	Closed	-$358K	–	653
2025 Q2	$358K	Buy	+2,882	New	+$367K	0.06%	310

Other funds holding RGEN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

111 Capital's RGEN Position: Q3 2025 in Review

111 Capital sold out of Repligen (RGEN) in Q3 2025, closing a stake of 2,882 shares — an estimated $358K sold.

111 Capital first reported a position in RGEN in Q2 2025 and held it in 1 quarter. The position peaked at $358K in Q2 2025. 453 funds tracked by Wall St. Rank hold RGEN as of Q3 2025.

111 Capital reported no remaining Repligen position as of Q3 2025 after selling out during the quarter.
111 Capital sold 2,882 Repligen shares in Q3 2025, an estimated $358K.
111 Capital first reported a position in Repligen in Q2 2025 and held it in 1 quarter.
111 Capital's Repligen position peaked at $358K in Q2 2025.
453 funds tracked by Wall St. Rank held Repligen as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.